Anti-P53 T-Cell Receptor-Transduced Peripheral Blood Lymphocytes
Unspecified Adult Solid Tumor, Protocol Specific
National Institutes of Health Clinical Center (CC)Cell therapyPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
18 Active assets in the Unspecified Adult Solid Tumor, Protocol Specific cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Amifostine M.D. Anderson Cancer Center | Phase 4 | BBB |
NEPENTHE M.D. Anderson Cancer Center | Phase 4 | BBB |
DEXAMETHASONE Alliance for Clinical Trials in Oncology | Phase 3 | BBB |
ETOPOSIDE University of California, Davis | Phase 2/3 | BBB |
FILGRASTIM National Institutes of Health Clinical Center (CC) | Phase 3 | BBB |
View all 50 →
Same molecule, other indications
Anti-P53 T-Cell Receptor-Transduced Peripheral Blood Lymphocytes is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →